Is it now time to prepare psychiatry for a psychedelic future?
David Nutt, Ilana B Crome, Allan H. Young
The British Journal of Psychiatry May 20, 2024 DOI: 10.1192/bjp.2024.76 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Depression MDMA Psilocybin PTSD |
| Keywords | Psychedelics Mental healthcare Psychedelic treatment MDMA Ecstasy Psilocybin magic |
| Citations | 18 |
| Key findings | Australia's rescheduling of psilocybin and MDMA creates both opportunities and challenges for psychiatry communities and health systems in responding to these developments. |
Abstract
Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. This feature explores the reasons for these developments, the opportunities and challenges they provide to psychiatry communities and how along with health systems these communities might respond to these developments.